RS63940B1 - Azelastin za antivirusno lečenje - Google Patents

Azelastin za antivirusno lečenje

Info

Publication number
RS63940B1
RS63940B1 RS20230083A RSP20230083A RS63940B1 RS 63940 B1 RS63940 B1 RS 63940B1 RS 20230083 A RS20230083 A RS 20230083A RS P20230083 A RSP20230083 A RS P20230083A RS 63940 B1 RS63940 B1 RS 63940B1
Authority
RS
Serbia
Prior art keywords
azelastine
antiviral treatment
antiviral
treatment
Prior art date
Application number
RS20230083A
Other languages
English (en)
Inventor
Eszter Nagy
Gábor Nagy
Valeria Szijarto
Robert Konrat
Original Assignee
CEBINA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20184767.0A external-priority patent/EP3936132A1/en
Application filed by CEBINA GmbH filed Critical CEBINA GmbH
Publication of RS63940B1 publication Critical patent/RS63940B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20230083A 2020-05-29 2021-05-28 Azelastin za antivirusno lečenje RS63940B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20177451 2020-05-29
EP20184767.0A EP3936132A1 (en) 2020-07-08 2020-07-08 Azelastine as antiviral treatment
EP20195740 2020-09-11
EP21171333 2021-04-29
EP21727186.5A EP3934653B1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment
PCT/EP2021/064338 WO2021239943A1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment

Publications (1)

Publication Number Publication Date
RS63940B1 true RS63940B1 (sr) 2023-02-28

Family

ID=76059910

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230083A RS63940B1 (sr) 2020-05-29 2021-05-28 Azelastin za antivirusno lečenje

Country Status (19)

Country Link
US (3) US20230201216A1 (sr)
EP (2) EP3934653B1 (sr)
JP (1) JP2023529025A (sr)
KR (1) KR20230021009A (sr)
CN (1) CN116406273A (sr)
AU (1) AU2021279280A1 (sr)
BR (1) BR112022023897A2 (sr)
CA (1) CA3184167A1 (sr)
DK (1) DK3934653T3 (sr)
ES (1) ES2937145T3 (sr)
FI (1) FI3934653T3 (sr)
HU (1) HUE060929T2 (sr)
IL (1) IL298543A (sr)
LT (1) LT3934653T (sr)
MX (1) MX2022015074A (sr)
PL (1) PL3934653T3 (sr)
RS (1) RS63940B1 (sr)
SI (1) SI3934653T1 (sr)
WO (1) WO2021239943A1 (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP2008285474A (ja) * 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
US20230129326A1 (en) * 2020-04-07 2023-04-27 University Of Florida Research Foundation, Incorporated Methods to prevent sars-cov-2 infection and treat covid-19
WO2021207729A1 (en) * 2020-04-10 2021-10-14 Mubarak Kamal Khan Compositions and methods for modulating ace2 receptor
CN113521289A (zh) * 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用

Also Published As

Publication number Publication date
HUE060929T2 (hu) 2023-04-28
CN116406273A (zh) 2023-07-07
SI3934653T1 (sl) 2023-04-28
LT3934653T (lt) 2023-02-27
IL298543A (en) 2023-01-01
JP2023529025A (ja) 2023-07-06
EP3934653B1 (en) 2022-11-09
ES2937145T3 (es) 2023-03-24
EP3934653A1 (en) 2022-01-12
US11273163B2 (en) 2022-03-15
US11433080B2 (en) 2022-09-06
KR20230021009A (ko) 2023-02-13
WO2021239943A1 (en) 2021-12-02
US20210369730A1 (en) 2021-12-02
MX2022015074A (es) 2023-02-16
AU2021279280A1 (en) 2023-01-05
DK3934653T3 (da) 2023-02-13
PL3934653T3 (pl) 2023-03-13
US20220143040A1 (en) 2022-05-12
BR112022023897A2 (pt) 2023-04-04
US20230201216A1 (en) 2023-06-29
FI3934653T3 (fi) 2023-03-01
CA3184167A1 (en) 2021-12-02
EP4190333A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
HUE060929T2 (hu) Azelasztin, mint antivirális kezelés
GB202108224D0 (en) Treatment
PT3934653T (pt) Azelastina como tratamento antiviral
GB202103122D0 (en) Treatment
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202003240D0 (en) Antiviral treatment
GB202116743D0 (en) Treatment
GB202114373D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202102488D0 (en) Treatment
GB202102369D0 (en) Treatment
GB202102366D0 (en) Treatment
GB202102410D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202101897D0 (en) Treatment
GB202101875D0 (en) Treatment
GB202101212D0 (en) Treatment
GB202101213D0 (en) Treatment
GB202101211D0 (en) Treatment